The effects of music therapy on amino acid neurotransmitters: Insights from an animal study

2020 ◽  
Vol 224 ◽  
pp. 113024
Author(s):  
Juanjuan Hao ◽  
Keyu Jiang ◽  
Min Wu ◽  
Jianer Yu ◽  
Xin Zhang
Keyword(s):  
Amino Acid ◽  
Music Therapy ◽  
Animal Study ◽  
Amino Acid Neurotransmitters

Application of the Innovative and Non-Invasive Technique, Molecular Music Therapy (MMT), Bio-Frequency Therapy, for the Treatment of a Wide Range of Disorders and Pathologies, with Consequent Verification of Molecular Parameters by Using Bi-Digital O-Ring Test (BDORT)

2020 ◽  
Vol 44 (3) ◽  
pp. 177-189
Author(s):  
Momir Dunjic ◽  
Stefano Turini ◽  
Dejan Krstic ◽  
Katarina Dunjic ◽  
Marija Dunjic ◽  
...  
Keyword(s):  
Amino Acid ◽  
Music Therapy ◽  
Amino Acid Sequences ◽  
Sirtuin 1 ◽  
Ring Test ◽  
Invasive Technique ◽  
Specific Gene ◽  
Radiofrequency Therapy ◽  
Wide Range ◽  
Clinical Pictures

Radiofrequency therapy is an unconventional method, already applied for some time, with numerous results in numerous clinical pictures. Our group has developed a software, later called SONGENPROT-SOLARIS, capable of directly converting nucleotide sequences (DNA and/or RNA) and amino acid sequences (polypeptides and proteins) into musical sequences, based on mathematic matrices, designed by the French physicist and musician Joel Sternheimer, which allows to associate a musical note with a nucleotide or an amino acid. Innovation in our software is that, in the algorithm that defines it, a variant is directly implemented that allows the reproduction of sounds, phase-shifted by 30 Hz, between one ear and another reproducing the phenomenon of Binaural Tones, capable of induce a specific brain activity and also the release of particles called solitons. Thanks to this software we have developed a technique called MMT (Molecular Music Therapy) and currently, we are in the phase of applying the technique on a cohort of 91 patients, with a high spectrum of clinical pictures, examining the same, using the technique Bi-Digital-ORing-Test (BDORT), before and after treatment with MMT. Aim of project is to stimulate the expression of a specific gene (the same genetic sequence that the patient listens to, translated into music), only through the use of sound sequences. We have concentrated our attention on three main molecules: Sirtuin-1, Telomers and TP-53. The results obtained with BDORT, after treatment with MMT, showed a significant increase in the values of the three molecules, on all the examined patients, demonstrating the operative efficacy of the technique and the its applicability to numerous diseases. In order to confirm the data obtained by BDORT, we propose, with the help of an accredited laboratory, to perform epigenetic tests on the three parameters listed above, paving the way to understanding how frequencies can influence gene expression.

scholarly journals Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders

2021 ◽  
Vol 5 ◽  
pp. 247054702110204
Author(s):  
Julia Hecking ◽  
Pasha A. Davoudian ◽  
Samuel T. Wilkinson
Keyword(s):  
Amino Acid ◽  
Mood Disorders ◽  
Phase Iii ◽  
Public Health Issue ◽  
Complex Nature ◽  
Novel Therapies ◽  
Amino Acid Neurotransmitters ◽  
Neurotransmitter System ◽  
Phase Iii Clinical Trials ◽  
The World

Mood disorders represent a pressing public health issue and significant source of disability throughout the world. The classical monoamine hypothesis, while useful in developing improved understanding and clinical treatments, has not fully captured the complex nature underlying mood disorders. Despite these shortcomings, the monoamine hypothesis continues to dominate the conceptual framework when approaching mood disorders. However, recent advances in basic and clinical research have led to a greater appreciation for the role that amino acid neurotransmitters play in the pathophysiology of mood disorders and as potential targets for novel therapies. In this article we review progress of compounds that focus on these systems. We cover both glutamate-targeting drugs such as: esketamine, AVP-786, REL-1017, AXS-05, rapastinel (GLYX-13), AV-101, NRX-101; as well as GABA-targeting drugs such as: brexanolone (SAGE-547), ganaxolone, zuranolone (SAGE-217), and PRAX-114. We focus the review on phase-II and phase-III clinical trials and evaluate the extant data and progress of these compounds.

Amino acid neurotransmitters in the central control of blood pressure and in experimental hypertension

1992 ◽  
Vol 10 ◽  
pp. S39 ◽  
Author(s):  
John Chalmers ◽  
Leonard Arnolda ◽  
Vimal Kapoor ◽  
Ida Llewellyn-Smith ◽  
Jane Minson ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Amino Acid ◽  
Experimental Hypertension ◽  
Central Control ◽  
Amino Acid Neurotransmitters

Photorelease of amino acid neurotransmitters from pyrenylmethyl ester conjugates

Tetrahedron ◽  
2007 ◽  
Vol 63 (41) ◽  
pp. 10133-10139 ◽  
Author(s):  
Maria J.G. Fernandes ◽  
M. Sameiro T. Gonçalves ◽  
Susana P.G. Costa
Keyword(s):  
Amino Acid ◽  
Amino Acid Neurotransmitters
Sign in / Sign up

Export Citation Format

Share Document